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Abstract
Background: Cardiac involvement in systemic sclerosis (SSc) is more prevalent than previously thought. In this study, the 
frequency and severity of cardiovascular involvement were assessed in SSc patients referred to Firouzgar Hospital. 
   Methods: Fifty-eight patients with SSc, selected from the data bank of SSc patients, were reviewed for the frequency and 
severity of 8 organ involvements in this case series.
   The preliminary severity scale, published by international SSc study groups, was employed for the determination of the 
severity grade in the cardiovascular system. In the cardiac scoring scale, grade 0 represents normal heart (no cardiac 
involvement), grade 1 denotes mild involvement [electrocardiography (ECG) conduction defect and a left ventricular ejection 
fraction (LVEF) of 45-49%)], grade 2 signifies moderate involvement (arrhythmia, LVEF = 40-44%), grade 3 indicates 
severe involvement (LVEF <40%)], and grade 4 stands for end stage (congestive heart failure and arrhythmia requiring 
treatment).
   Results: In this study, 24 (41.4%) patients were in the diffuse cutaneous (dcSSc) subset. The female to male ratio was 10.5:1, 
and the mean duration from symptom onset to diagnosis was 7.35 years for the dcSSc subset and 8.41 years for the limited 
cutaneous (lcSSc) subset of disease, there being no significant difference. Cardiac involvement in this series was seen in 13 
(22.4%) cases; and there was no significant difference in terms of frequency and severity between the two disease subgroups 
(p value = 0.96 and p value = 0.46 respectively).
   Conclusion: Our findings showed that the cardiac involvement in this series was infrequent and that there was no significant 
difference in the severity of cardiovascular involvement between the two subtypes of SSc in the late stage of the disease.
   J Teh Univ Heart Ctr 1 (2010) 14-18
Received 28 July 2009; Accepted 10 November 2009
Keywords: Scleroderma, systemic • Connective tissue diseases • Heart 
Introduction
systemic sclerosis (SSc) is a connective tissue disorder 
characterized by vascular lesion and widespread fibrosis in 
organs such as skin, gut, lung, heart, and kidneys. Clinically, 
there is a broad spectrum of symptoms from widespread 
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severe skin thickening (diffuse) to skin thickening limited to 
distal extremities and/or face (limited). In the diffuse form, 
skin involvement is limited to hands, body, and face; whereas 
in the limited form, skin involvement is limited to hands and 
extremities lower than elbows and knees. 
Cardiac involvement in SSc seems to be more prevalent 
than previously thought,1 as shown by improved invasive 
and non-invasive diagnostic techniques for detecting heart 
disease.2-5 Cardiopulmonary, renal, and extensive skin 
involvement is poor prognosis and the leading cause of early 
death in SSc.6
To determine the abundance of cardiac involvement, 
the present study drew upon such different modalities as 
autopsy, exercise test, radioisotope scan, chest X-ray, ECG, 
and echocardiography.6-8 The severity of cardiac disease 
is usually determined using the two scoring methods of 
Clement and Medsger. The former is currently less favored 
in clinical trials, but the latter is regarded as more practical 
and is accepted by international SSc study groups.
The present study was designed to address the dearth of 
data on the severity and frequency of cardiac involvement in 
SSc patients in Iran.
Patients and methods
The SSc data bank in Firouzgar Hospital Rheumatology 
Department contains information on 67 patients (Until 
January 2007). Patients fulfilling the preliminary criteria of 
the American Rheumatism Association were recruited into 
this study, and 4 patients diagnosed as having SSc overlap 
with other connective tissue disease in addition to 5 patients 
whose cardiac involvement was secondary to pulmonary 
involvement were excluded. In total, 58 patients were 
included in the study.
During a 6-month period after the first visit to our clinic, 
core set variables of all the patients in this case series were 
assessed to define each organ system involvement. For cardiac 
involvement, traditional criteria hinging on the presence of 
1 or more dichotomous variables, i.e. presence or absence of 
cardiomegaly, pericardial effusion, ventricular arrhythmias, 
conduction disturbances, axis deviations, and pathological 
Q waves (myocardial necrosis), were employed.2, 6 For 
cardiac severity, the preliminary severity scale, published by 
international SSc study groups, was utilized and the patients’ 
files were reviewed retrospectively.8-10 The preliminary scale 
introduced by Medsger proposes a 9-organ disease severity 
scale for SSc, with “severity” defined as the total effect 
of the disease on the organ function. The scale has both 
irreversible (damage) and reversible components (activity), 
and the severity grading for each organ system ranges from 
0 (no document) to 4 (end-stage disease).  
In the cardiac scoring scale, grade 0 represents normal 
heart (no cardiac involvement), grade 1 denotes mild 
involvement [electrocardiography (ECG) conduction defect 
and a left ventricular ejection fraction (LVEF) of 45-49%], 
grade 2 signifies moderate involvement (arrhythmia, LVEF 
= 40-44%),8, 9 grade 3 indicates severe involvement (LVEF 
<40%), and grade 4 stands for end stage (congestive heart 
failure and arrhythmia requiring treatment).
For the cardiac severity scale, each variable was primarily 
attributed to SSc rather than to another disorder. For 
example, if patients with mild (grade 1) cardiac involvement 
developed superimposed bacterial pneumonia with transient 
severe dyspnea and fibrillation (grade 2, moderate) due to 
hypoxia , the cardiac score was evaluated after pneumonia 
had resolved.
The relationship between cardiac involvement severity 
(cardiac scoring) and disease stage was assessed by analyzing 
the time periods in two disease subsets:  early and late stages 
of the disease. Early stage was defined as diffuse cutaneous 
(dcSSc) < 3 years and limited cutaneous (lcSSc) < 5 years.
The analyses were performed using SPSS software version 
9 released for microcomputers. The chi-square test was used 
for the detection of any correlation between cardiac severity 
and the two subsets of scleroderma, and the Fisher exact 
test was employed for the comparison of cardiac severity 
in the early and late stages of the 2 disease subsets. The 
Kendall Tau correlation coefficient was used to assess the 
correlation between cardiac severity and severity of other 
organ involvement.
Results
Table 1 depicts the general characteristics of the patients. 
There were 58 patients with a mean age ± SD of 40.9±13.7 
years and a female to male ratio of 53/5, of whom 24 (41.4%) 
patients were in the dcSSc subset. The mean total skin score 
in all the patients was 16.6, based on the modified Rodnan 
scoring system, and the mean duration from symptom 
onset to study entry was 7.3±8.5 years for the dcSSc and 
8.4±8.2 years for the lcSSc subsets; there was no statistically 
significant difference (p value = 0.638). 
dcSSc subset
Table 1. Comparisons of clinical characteristics in two subsets of patients  
Number of patients (%)
Age (y) (mean±SD)
Female/male

















*p value < 0.0001
**Form the onset to the first visit 
lcSSc subset, Limited cutaneous subset; dcSSc subset, Diffuse cutaneous 
subset
totallcSSc subset
Table 2 illustrates the characteristics of cardiac involve-
ment in the patients. Cardiac involvement was detected in 13 
(22.4%) and conductive disturbance in 6 (10.3%) out of the 
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58 SSc study patients. Axis deviation was found in 6 (10.3%) 
patients, all with left axis deviation. Additionally, abnormal 
Q waves and arrhythmia were found in 1 (1.7) and 2 (3.5) 
patients, respectively.
Cardiomegaly on chest x-ray, echocardiography, or ECG 
was found in 10 (17.2%) patients: 4 in the limited and 6 in 
the diffuse disease subtypes. Echocardiography revealed 
pericardial effusion in 9 (15.5%) patients, with a moderate-
to-severe degree of pericardial effusion in 3 (5.1%) persons. 
As Table-3 demonstrates, there was no difference in terms of 
cardiac involvement between the 2 forms of scleroderma.
dcSSc subset
Table 2. Cardiac characteristics of the patients  
Axis deviation
    Normal axis 
    LAD




    None
    LBBB
    LAHB
    RBBB + LAHB
    Complete hemi block
Cardiomegaly
Pericardial effusion
    None 
    Mild
    Moderate














































*Numbers in the parenthesis are the related percentages  
lcSSc subset, Limited cutaneous subset; dcSSc subset, Diffuse cutaneous 
subset; LAD, Left axis deviation; RAD, Right axis deviation; LBBB, Left 




Table 3. Severity grade and stage of the disease in two subsets of systemic 



























*< 3 years in diffuse cutaneous subset and < 5 years in limited cutaneous 
subset
**> 3 years in diffuse cutaneous subset and > 10 years in limited cutaneous 
subset
Limited SScSeverityStage
With respect to the cardiac severity scoring of the patients, 
45 (77.6%) patients scored zero (normal heart); cardiac 
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involvement in 13 of the 58 (22.4%) patients was detected. 
Seven and 5 patients in the limited and diffuse disease 
subsets, respectively, had mild cardiac involvement (grade 
1); moderate to severe cardiac involvement was not observed 
in either of the two subsets; and only 1 patient with diffuse 
skin involvement had end-stage cardiac involvement. A 
comparison of the limited and diffuse subsets of patients with 
no cardiac involvement as group 1 and the others with mild-
to-severe involvement as group 2 yielded no statistically 
significant difference (p value = 0.96) 
In regard to the relationship between the severity of cardiac 
involvement and that of other systems, cardiac severity 
showed no correlation with the severity of dermal, peripheral 
vascular, renal, tendinous, muscular, and gastrointestinal 
systems. There was, however, a significant correlation 
between cardiac severity and pulmonary severity (Kendall 
Tau = 0.27, p value = 0.04). The relationship between cardiac 
severity (cardiac scoring) and disease stage in the two disease 
subsets was evaluated, and the time scales were analyzed in 
the two disease subsets in terms of early and late stages; early 
stage was defined as dcSSc < 3 years and lcSSc < 5 years. 
There were 8 (23.5) patients with the dcSSc subtype in the 
early disease stage < 3 years (Table 3). There was no difference 
in the severity grade of the two disease subtypes between the 
early and late stages (in early stage: p value = 0.136 and 
α2 = 3.564; in late stage: p value = 0.433 and α2  = 0.332).
Discussion 
The female to male ratio in the present study population at 
a mean age±SD of 40.9±13.7 years was 53/5, which does not 
chime in with the results of pervious epidemiological studies 
of SSc reporting that the disease is 3-4 times more common 
in women. Nonetheless, the onset of SSc in this study is in 
the fourth and fifth decades of life as is the case in other 
similar studies.11, 12 The mean disease duration from onset 
to entry in the lcSSc and dcSSc subtypes was 8.4 and 7.3 
years, respectively. This means that the patients referred for 
treatment in the late disease stages, contributing to sample 
collection bias in the present study.
From a total of 58 SSc patients, 13 (22.4%) persons were 
found to have cardiac involvement and most of these patients 
(12/13 [92%]) showed mild severity of involvement.
In the Janosik et al.13 study, pathological involvement of 
the pericardium was observed in 70%-80% of the patients at 
autopsy, while clinical manifestation was present in 7%-20% 
of the study subjects. They reported an association between 
pericardial effusion and cardiac involvement; pericardial 
effusions were small or large and had developed rapidly in 
some cases due to renal failure.
Echocardiography revealed pericardial effusion in 9 
(15.5%) patients, moderate-to-severe pericardial effusion in 3 
(5.1%) patients, and no renal failure in our study population. 
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It is deserving of note that echocardiography tends to be 
abnormal in 50% of patients and includes evidence of 
pericardial thickening or fluid, while clinical presentations 
of pericarditis and of tamponade are infrequent.16 In this 
series, we found axis deviation in 6 (10.3%) patients, all with 
left axis deviation. Arrhythmia and abnormal Q waves were 
present in 2 and 1 patient in each disease subset. 
In the Kostis J.B. et al.14 study, electrocardiography 
abnormalities, including arterial and ventricular 
arrhythmias and conduction disturbances by ambulatory 
electrocardiography study, confirmed a high prevalence of 
both supraventricular and ventricular tachyarrhythmia. In 
our study, cardiomegaly on chest x-ray, echocardiography, 
or ECG were found in 10 (17.2%) patients: 4 in the limited 
and 6 in the diffuse disease subtypes. In the Clements P. J. et 
al. 15 study of 90 patients, 44 ( 49%) patients were found with 
cardiac involvement , which was comprised of arrhythmia 
in 4 (4.4% ), cardiomegaly in 16 (17.8%) , conduction defect 
in 9 (10%), pericardial effusion  in 9 (10%), axis deviation 
in 18 (20%),  and pathological Q wave in 12 (13.3%). The 
SD of the duration of SSc prior to entry was 6.6±7.8 years, 
and 39 patients entered the study within 3 years of disease 
onset.  In a study of cardiac involvement by Geirsson A. J. 
et al.,16 40 patients with SSc and disease duration of 6 years 
were included in study. Cardiomegaly and arrhythmia at rest 
were 57% and 7.5% in the diffuse and CREST syndrome, 
respectively.
There were 9 (15.5%) patients with mild-to-severe 
pericardial effusion in our study as opposed to the 17.6% 
figure in the Pittsburgh study;8 the incidences of pericarditis 
were, however, similar. In the MC Whorter et al.17 study, 
the incidence of pericardial effusion was 50% and that of 
tamponade was not high as well.
Coronary involvement was evaluated via non-invasive 
procedures in the present study, and no serological correlation 
with specific auto-antibodies was done, which can be deemed 
a limitation of our study.
Forty-five (77.6%) of our study population scored zero 
for cardiac involvement (normal heart). As was mentioned 
above, evidence for cardiac involvement was relatively 
infrequent;  a comparison between the limited and diffuse 
subsets of patients with no cardiac involvement as group 1 
and  the others with mild-to-severe involvement as group 2 
yielded no difference in terms of frequency between the two 
groups  (P value = 0.46).
An assessment of the relationship between the severity of 
cardiac involvement (cardiac scoring) and lung involvement 
showed no correlation with the severity of skin involvement. 
Visceral involvement in the diffuse subset patients was high 
in the early disease stage and skin stiffness was low in the late 
stage. Visceral involvement gradually decreased but did not 
cure spontaneously. In the existing literature, the incidence 
of visceral involvement in the limited form is similar to that 
of the diffuse form except for renal and dermal involvement, 
which is gradual.18-20 By contrast, 66.7% of the patients 
in the diffuse subset in the present study were in the late 
disease stage, denoting the lack of a relationship between 
skin involvement and severity of lung and cardiac disease. 
On the other hand,  skin severity is not a good indicator of 
the severity of visceral organ involvement, especially in the 
late stage. This is concordant with the results of the Ferri C 
et al. 21 study.   
We found no difference in the severity of cardiac 
involvement between the two disease subsets in the early and 
late stages. This result may be in consequence of either the 
low incidence of cardiac involvement, rendering the number 
of cases in each disease stage insufficient to divulge any 
difference, or collection bias as the patients were recruited 
into the study long after the disease onset. 
In the Furst et al.22 study, patients with progressive SSc 
were matched for sex, age, and disease duration and the 
results showed a relationship between muscle involvement 
and severity of skin disease.  
A point of significance is that the present study represents 
only a small group of SSc patients in Iran. Furthermore, the 
fact that the majority (55%) of our patients were in the late 
disease stage precludes any generalization of the results. 
Conclusion
The present study represents a baseline estimate of 
the occurrence and severity of cardiac involvement in a 
small group of Iranian SSc patients. In this case series of 
58 patients, a low incidence of cardiac involvement was 
detected. Our study also demonstrates the relative ease and 
applicability of severity scale measures for an assessment of 
cardiac involvement in SSc sufferers.  The existing literature 
bears testament to the importance of such instruments in 
clinical trials.
Future studies are required to shed further light on the 
correlation between cardiac involvement and severity and 
specific auto-antibodies in scleroderma.
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